Gilles Salles
Memorial Sloan Kettering Cancer Center
1015 Papers
4.9K Citations
Gilles Salles is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Medicine & Follicular lymphoma. The author has an hindex of 99, co-authored 854 publications. Previous affiliations of Gilles Salles include École normale supérieure de Lyon & Centre national de la recherche scientifique.
Chat about Author
Papers
Impact of doxorubicin dose capping on the outcome of DLBCL patients with elevated Body Surface Area
Richard Delarue,Noel Milpied,Lucie Oberic,Bertrand Coiffier,Sami Boussetta,Corinne Haioun,Hervé Tilly,Gilles Salles,Thierry Lamy,Marie-Antoinette Lester,Roch Houot +10 more
TL;DR: To the editor: In 2012, the American Society of Clinical Oncology (ASCO) published guidelines regarding the dosing of chemotherapy for obese patients with cancer.[1]
4
Pseudo-Progression Among Patients with Follicular Lymphoma Treated with Ibrutinib in the Phase 2 DAWN Study
Gilles Salles,Judith Trotman,Michael Lill,Bruce D. Cheson,Stephen J. Schuster,Jing-Zhou Hou,John Radford,Andrew Spencer,Michael Schaffer,Rajendra N. Damle,Gary J. Gartenberg,Jessica Vermeulen,Sriram Balasubramanian,Sanjay Deshpande,Dolores Caballero +14 more
TL;DR: A protocol amendment was made to address the novel situation of delayed responses that were observed after PD to allow for continuation of ibrutinib treatment in patients with radiological evidence of PD who were clinically stable/improving/exhibiting signs of tumor flare without documented PD by other methods.
4
Phase I Study of Escalating Doses of Lenalidomide Combined with R-CHOP (R2-CHOP) for Front-Line Treatment of B-Cell Lymphomas
Hervé Tilly,Franck Morschhauser,Gilles Salles,Rene-Olivier Casasnovas,Serge Bologna,Thierry Jo Molina,Corinne Haioun,Bertrand Coiffier +7 more
TL;DR: The combination of 25mg of lenalidomide during 14 days with 21-day R-CHOP cycles has an acceptable safety profile in patients with B-cell lymphoma.
4
Long Term Follow-up of the GELF86 French and Belgian Trials : Complete Remission after First Line Treatment with Conventional Chemotherapy in Newly Diagnosed Follicular Lymphoma Patients Correlates with Prolonged Overall Survival Compared with Partial Remission.
Emmanuel Bachy,Pauline Brice,Marion Fournier,H. Tilly,Corinne Haioun,Nicole Brousse,S. Le Gouil,André Bosly,B. Coiffier,Christian Gisselbrecht,Philippe Solal-Celigny,Gilles Salles +11 more
TL;DR: There is strong evidence that better response to first line treatment translates into a favorable outcome for patients with newly diagnosed follicular lymphoma, especially for HTB patients.
4
Characteristics of Refractory and Relapsing Patients with Diffuse Large B-Cell Lymphoma.
Bertrand Coiffier,Gilles Salles,André Bosly,Philippe Gaulard,Corinne Haioun,Olivier Casasnovas,Nicolas Mounier,Marie Helene Delfau,Catherine Sebban,Pierre Feugier,Christian Recher,Richard Delarue,Nicolas Ketterer,Hervé Tilly,Christian Gisselbrecht +14 more
TL;DR: All patients with aggressive lymphoma included in the GELA trials during the last 20 years or 4 generations of studies were looked at, finding 2 patterns of failing therapy: refractory or non-responding pts and patients in PR at the end of treatment and relapsing pts with early relapses.
4